In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Heart Failure 2021 and Beyond - Optimising Outcomes in Heart Failure

CRT Online Workshop - 2 afternoon sessions from 14:00 - 17:30 CEST

16/09/2021 14:00 17/09/2021 17:30 Europe/Paris Heart Failure 2021 and Beyond - Optimising Outcomes in Heart Failure

Access event page DD/MM/YYYY


Chairpersons: Prof. Ewa Jankowska (Heart Failure Association of the ESC), Prof. John McMurray (ESC),
Dr. Claudia Kaiser-Albers (MSD), Dr. Tomas Andersson (AstraZeneca).


Objectives of the workshop

  • Discuss and align challenges and opportunities facing the development of new medicines and technologies for heart failure.
  • Identify hurdles in implementation and approaches to overcome them.
  • Define what needs to be modified/changed/optimised in the development and implementation of the new guidelines.

Session 1

Session 2

Session 3


Patient perspective: What matters to Heart Failure patients?



View faculty biographies

DAY 1 – 16 September 2021 - 14:00-17:15 CEST

The evidence and the implementation of ESC Clinical Practice Guidelines

Chaired by Prof. E. Jankowska and Dr. T. Andersson

16 September

14:00 - 14:10

Introduction: Goals of the CRT and objectives of the workshop

Dr. C. Kaiser-Albers

SESSION 1 - ESC Clinical Practice Guidelines 2021 - Where do we stand and what evidence do we stand on? 

Moderated by Prof. E. Jankowska and Dr. T. Andersson

14:10 - 14:25

Presentation of the new Guidelines 

Prof. M. Metra (IT) and Prof. T. McDonagh (UK)

14:25 - 14:35

The concept of a universal definition of heart failure

Why and what it means in practice

A joint venture of HFA/HFSA/JHFS societies

Prof. B. Bozkurt (US)

14:35 - 14:55

Reflections on the Guidelines and how they are Implemented
How well did we do in the last five years?
Examples of Entresto and ICD/CRT

Prof. J. McMurray and Prof. W. Mullens (BE)

14:55 - 15:05

How do we improve implementation of evidence in practice?
Perspectives from outside western Europe

Dr. O. Chioncel (RO)

15:05 - 15:45

Panel discussion including academia, industry, payers, regulatory, patients


15:45 - 16:00


16:00 - 17:00

Breakout Sessions : Moderated by appointed experts and discussants
Why is the uptake of life-saving treatments for heart failure still sub-optimal?

17:00 – 17:15

Summary of pitches - Wrap-up Day 1 - Outlook on Day 2

Prof. E. Jankowska and Dr. C. Kaiser-Albers

DAY 2 – 17 September 2021 - 14:00-17:30 CEST

Optimising outcomes in heart failure 

Chaired by Prof. J. McMurray and Dr. C. Kaiser-Albers

14:00 - 14:15

Summary of Day 1 - Viewpoints from the Breakout Sessions
What else are the hot topics in heart failure?

Dr. C. Kaiser-Albers and Dr. T. Andersson

SESSION 2 - Optimising outcomes in heart failure: what else?

Moderated by Prof. J. Mc Murray and Dr. C. Kaiser-Albers

14:15 - 14:25

What do we mean by “HFpEF” in 2021 and how should it be treated?

Prof. S. Solomon (US)

14:25 - 14:35

Should we bother about the treatment advances: Quality of life and functional capacity?

Prof. A. Coats (UK)

14:35 - 14:45

How do we measure QoL and assess functional capacity?

Dr. L. Hill (UK)

14:45 - 14:55

Patient perspective: What matters to me?
Video interview with a patient

14:55 - 15:05

How can regulators and payers contribute to optimise outcomes?
 - The EMA perspective

Dr. C. Mittmann (DE)

15:05 - 15:15

How can regulators and payers contribute to optimise outcomes?
 - A general perspective of payers

Prof. U. Siebert (AT)

15:15 - 15:45

Panel / Moderated discussion with panelists and experts representing a geographical diversity

15:45 - 16:00


SESSION 3 - Going digital – Will it shake everything up?

Moderated by Prof. M. Cowie and Prof. A. Goncalves (Philips)

16:00 - 17:30

Quick perspectives:

16:00 - 16:10

Will digital tools help patients manage their disease better? Lifestyle, treatment and awareness of disease fluctuations

Prof. M. Volterrani (IT)

16:10 - 16:20

Can we capture clinical status, activity levels and treatment adherence remotely?

Prof. F. Koehler (DE)

16:20 - 16:30

Education, implementation, adherence, monitoring and outcomes - The digital future of cardiology

Dr. R. Califf (US)

16:30 - 16:40

Digital clinical trials – Patient enrolment, monitoring and collection of follow-up data

Prof. L. Lund (SE)

16:40 - 17:15

Panel Discussion - Could we have a common digital platform to deliver routine care and conduct clinical trials?

17:15 - 17:30

Key take-home messages / Recommendations for preparation of the publication